1. DOP40 Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn's disease treated with upadacitinib. (30th January 2023) Authors: Dubinsky, M C; D'Haens, G; Dewit, O; Juillerat, P; Panaccione, R; Fujii, T; Lacerda, A P; Dubcenco, E; Anyanwu, S; Doshi, C; Mallick, M; Garrison, A; Liu, J; Loftus Jr, E V Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗